Matisse Pharmaceuticals
Clinical biopharma for treating sepsis and septic shock.
About Matisse Pharmaceuticals
Geleen-based biotech developing M6229, a first-in-class therapy that neutralizes cytotoxic histones in the bloodstream. Active clinical program at Chemelot / Brightlands cluster.
